JPWO2021067775A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021067775A5 JPWO2021067775A5 JP2022520447A JP2022520447A JPWO2021067775A5 JP WO2021067775 A5 JPWO2021067775 A5 JP WO2021067775A5 JP 2022520447 A JP2022520447 A JP 2022520447A JP 2022520447 A JP2022520447 A JP 2022520447A JP WO2021067775 A5 JPWO2021067775 A5 JP WO2021067775A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- seq
- formulation according
- histidine
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025010928A JP2025061811A (ja) | 2019-10-02 | 2025-01-24 | 抗コネキシン抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909267P | 2019-10-02 | 2019-10-02 | |
| US62/909,267 | 2019-10-02 | ||
| PCT/US2020/054036 WO2021067775A1 (en) | 2019-10-02 | 2020-10-02 | Anto-connexin antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010928A Division JP2025061811A (ja) | 2019-10-02 | 2025-01-24 | 抗コネキシン抗体製剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022552152A JP2022552152A (ja) | 2022-12-15 |
| JP2022552152A5 JP2022552152A5 (https=) | 2023-10-10 |
| JPWO2021067775A5 true JPWO2021067775A5 (https=) | 2023-10-10 |
| JP7805289B2 JP7805289B2 (ja) | 2026-01-23 |
Family
ID=75273959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520447A Active JP7805289B2 (ja) | 2019-10-02 | 2020-10-02 | 抗コネキシン抗体製剤 |
| JP2025010928A Pending JP2025061811A (ja) | 2019-10-02 | 2025-01-24 | 抗コネキシン抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010928A Pending JP2025061811A (ja) | 2019-10-02 | 2025-01-24 | 抗コネキシン抗体製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12358981B2 (https=) |
| EP (1) | EP4037703A4 (https=) |
| JP (2) | JP7805289B2 (https=) |
| KR (1) | KR20220113355A (https=) |
| CN (1) | CN114786719A (https=) |
| AU (1) | AU2020358101A1 (https=) |
| CA (1) | CA3156812A1 (https=) |
| WO (1) | WO2021067775A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| WO2022026914A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| CN115825201B (zh) * | 2022-07-28 | 2024-10-25 | 苏州凯劳生物科技有限公司 | 一种使用毛细管电泳仪电离还原蛋白二硫键并确定其自由巯基比例的方法 |
| WO2025199516A1 (en) * | 2024-03-22 | 2025-09-25 | Board Of Regents, The University Of Texas System | Compositions and methods for preserving or increasing lean muscle mass |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4063769B2 (ja) | 2001-12-28 | 2008-03-19 | 中外製薬株式会社 | タンパク質安定化方法 |
| NZ547157A (en) | 2003-12-10 | 2009-07-31 | Medarex Inc | Interferon Alpha Antibodies and their uses |
| CN1981054A (zh) * | 2004-05-14 | 2007-06-13 | 加利福尼亚大学董事会 | 用抗wnt2单克隆抗体和sirna治疗癌症的方法 |
| MX2010012324A (es) * | 2008-05-15 | 2011-01-14 | Biogen Idec Inc | Anticuerpos anti-fn14 y usos de los mismos. |
| RU2408728C1 (ru) * | 2009-07-28 | 2011-01-10 | Федеральное государственное учреждение "Государственный Научный Центр Социальной и Судебной Психиатрии им. В.П. Сербского" (ФГУ "ГНЦССП Росздрава") | Способ получения иммуногенного рекомбинантного экстраклеточного фрагмента коннексина-43 |
| CA2806157C (en) | 2010-07-26 | 2016-11-22 | Les Laboratoires Servier | Methods and compositions for liver cancer therapy |
| RU2457862C1 (ru) * | 2011-07-07 | 2012-08-10 | Федеральное государственное учреждение "Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения низкодифференцированных глиом |
| CN114621346B (zh) | 2013-08-21 | 2025-06-10 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
| IN2014MU01248A (https=) | 2014-04-02 | 2015-10-09 | Intas Pharmaceuticals Ltd | |
| CN107109410B (zh) | 2014-08-22 | 2021-11-02 | 奥克兰联合服务有限公司 | 通道调节剂 |
| WO2017147561A1 (en) * | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CA3095897A1 (en) | 2018-04-02 | 2019-10-10 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| US11427639B2 (en) * | 2018-04-02 | 2022-08-30 | Richter Gedeon Nyrt. | Antibody-containing aqueous formulation and use thereof |
-
2020
- 2020-10-02 KR KR1020227014499A patent/KR20220113355A/ko active Pending
- 2020-10-02 JP JP2022520447A patent/JP7805289B2/ja active Active
- 2020-10-02 AU AU2020358101A patent/AU2020358101A1/en active Pending
- 2020-10-02 EP EP20872009.4A patent/EP4037703A4/en active Pending
- 2020-10-02 WO PCT/US2020/054036 patent/WO2021067775A1/en not_active Ceased
- 2020-10-02 CN CN202080082579.4A patent/CN114786719A/zh active Pending
- 2020-10-02 US US17/061,918 patent/US12358981B2/en active Active
- 2020-10-02 CA CA3156812A patent/CA3156812A1/en active Pending
-
2025
- 2025-01-24 JP JP2025010928A patent/JP2025061811A/ja active Pending
- 2025-06-11 US US19/235,455 patent/US20260049132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7256234B2 (ja) | 高濃度抗体含有溶液製剤 | |
| KR102641565B1 (ko) | 분지형 링커를 갖는 튜불리신 유사체의 접합체 | |
| TWI883117B (zh) | Ｔｕｂｕｌｙｓｉｎ衍生物與細胞結合分子偶聯物的製劑配方 | |
| JP2021512881A5 (https=) | ||
| ES2349779T3 (es) | Formulaciones de anticuerpos y de proteínas a concentración elevada. | |
| KR101944211B1 (ko) | 안정화 항체 함유 용액 제제 | |
| JP6053969B2 (ja) | ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤 | |
| JP2020138981A5 (https=) | ||
| EP2099489B1 (en) | Compositions and methods for treating a neoplasm | |
| ES3038408T3 (en) | Formulations with reduced degradation of polysorbate | |
| JP2017222654A (ja) | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 | |
| JPWO2019157340A5 (https=) | ||
| FR2995214A1 (fr) | Solution a viscosite reduite de proteine a concentration elevee | |
| RU2020112302A (ru) | Соединения для уменьшения вязкости биологических композиций | |
| JP2020532562A5 (https=) | ||
| JP2010511665A5 (https=) | ||
| TW202003046A (zh) | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 | |
| AU2009312235A1 (en) | Aqueous composition containing follicle-stimulating hormone | |
| US20060246060A1 (en) | Novel stable formulation | |
| JPWO2021067775A5 (https=) | ||
| JP2023500697A (ja) | プラチナベースの薬剤と抗組織因子抗体－薬物コンジュゲートの組み合わせを用いるがんの治療方法 | |
| ES2808823T3 (es) | Formulaciones con oxidación reducida | |
| JPWO2022026914A5 (https=) | ||
| WO2003018056A1 (fr) | Preparations stabilisees contenant un anticorps | |
| HRP20240176T1 (hr) | Formulacije |